

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification³ : A61K 31/56	A1	(11) International Publication Number: WO 85/ 02543 (43) International Publication Date: 20 June 1985 (20.06.85)
(21) International Application Number: PCT/US84/01977 (22) International Filing Date: 30 November 1984 (30.11.84) (31) Priority Application Number: 560,726 (32) Priority Date: 12 December 1983 (12.12.83) (33) Priority Country: US (71)(72) Applicant and Inventor: KASZYNSKI, Edwin, G. [US/US]; 12928 Dean Road, Wheaton, MD 20902 (US). (72) Inventors: BREUER, Miklos, M. ; 108 Ridge Avenue, Newton, MA 02159 (US). SHANDER, Douglas ; 5 Meadowgrass Court, Gaithersburg, MD 20878 (US). USDIN, Vera, R. ; 6 Stevens Court, Rockville, MD 20850 (US). VAN DER LEE, Hermes ; 13129 Hol-dridge Road, Silver Spring, MD 20906 (US).		(74) Agents: HANDELMAN, Joseph, H. et al.; Ladas & Parry, 26 West 61 Street, New York, NY 10023 (US). (81) Designated States: AU, CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), JP, NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: HAIR GROWTH MODIFICATION (57) Abstract The rate and character of androgen-stimulated beard hair growth in intact, sexually mature male is altered by the topical application out of a dermatologically acceptable carrier of an antiandrogen material. In a preferred practice of the invention, compositions containing both a steroid 5-alpha-reductase inhibitor and a cytoplasmic androgen receptor-binding agent are employed.		

-12-

C L A I M S

1. A topical composition for altering the rate and character of androgen-stimulated hair growth, which comprises at least one antiandrogen agent consisting of a 5-alpha-reductase inhibitor or a cytoplasmic androgen receptor-binding agent or a mixture thereof, and a dermatologically acceptable carrier, the formulation of said carrier and the concentration of said antiandrogen agent being selected to effectively alter the rate and character of androgen-stimulated beard hair growth in intact, sexually mature males upon application to the skin and to provide a local effect with minimal alteration of other androgen-mediated bodily functions through systemic action.
2. A composition as described in claim 1, in which the 5-alpha-reductase inhibitor is progesterone; (5 α ,20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one; (4R)-5-10-seco-19-Norpregna-4,5-diene-3,10,20 trione; 4-androstene-3-one-17 β -carboxylic acid, or its methyl ester; 17- β -N,N-diethylcarbamoyl-9-methyl-4-aza-5 α -androstane-3-one; 11- α -OH-progesterone; 17- α -OH-progesterone; or 20- α -OH-progesterone.
3. A composition as described in claim 2, wherein the concentration of said antiandrogen agent is selected to result in the application of from about 10 to about 10,000 micrograms of 5-alpha-reductase inhibitor per square centimeter of skin.
4. A composition as described in claim 2, wherein the concentration of said antiandrogen agent is selected to result in the application of from about 100 to about 1,000 micrograms of 5-alpha-reductase inhibitor per square centimeter of skin.
5. A composition as described in claim 1, in which the cytoplasmic androgen receptor-binding agent is cyproterone acetate, chlormadinone acetate, 17-alpha-propyltestosterone; 17-alpha-allyltestosterone; α - α - α -trifluoro-2-methyl-4'-nitro-m-propionotoluidide; 6 α -bromo-17 β -hydroxy-17 α -methyl-4-oxa-5 α -androstane-3-one; 17 β -acetoxo-4 α ,5cyclo-A-homo-B-nor-5 α -androst-1-ene-3-one; or spironolactone.



-13-

6. A composition as described in claim 5, wherein the concentration of said antiandrogen agent is selected to result in the application of from about 0.1 to about 5,000 micrograms of the cytoplasmic androgen receptor-binding agent per square centimeter of skin.
7. A composition as described in claim 5, wherein the concentration of said antiandrogen agent is selected to result in the application of from about 1.0 to 500 micrograms of cytoplasmic androgen receptor-binding agent per square centimeter of skin.
8. A composition as described in any one of the preceding claims, in which a 5-alpha-reductase inhibitor is used along with a cytoplasmic androgen receptor-binding agent.
9. A topical composition for altering the rate and character of androgen-stimulated hair growth, comprising a 5-alpha-reductase inhibitor consisting of progesterone or 4-androstene-3-one-17 β -carboxylic acid and a cytoplasmic androgen receptor-binding agent consisting of 17-alpha-propyltestosterone or 17-alpha-allyltestosterone, said 5-alpha-reductase inhibitor and said cytoplasmic androgen receptor-binding agent being formulated in a dermatologically acceptable carrier, the concentrations of said 5-alpha-reductase inhibitor and said cytoplasmic androgen receptor-binding agent each being from about 0.1% to about 10.0% by weight of the composition.
10. A composition as described in claim 9, in which the concentration of said 5-alpha-reductase inhibitor is from about 0.5 to about 5.0% by weight of the composition and in which the concentration of said cytoplasmic androgen receptor-binding agent is from about 0.02 to about 0.5% by weight of the composition.
11. A process for altering the rate and character of androgen-stimulated beard hair growth in intact, sexually mature males, which comprises applying to the skin a composition according to any one of the preceding claims.
12. The use of a composition according to any one of the preceding claims 1 to 10, to alter the rate and character

SUBSTITUTE SHEET



-14-

of androgen-stimulated beard hair growth in intact, sexually mature males.

SUBSTITUTE SHEET



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 84/01977

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ¹ According to International Patent Classification (IPC) or to both National Classification and IPC ²		
A61K 31/56 424/240		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	424/240	
Documentation Searched other than Minimum Documentation to the extent that such Documents are Included in the Fields Searched ⁵		
(1) CAS-On line computerize Search (2) Mead-Lexis computerize Search		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁵ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	US,A4,098,802 published July 4, 1978 by van der Vies	1-10
X	US,A4,310,523 published Jan. 12, 1982 by Friedmund Neumann	1-10
X	US,A4,039,669 published Aug. 2, 1977 by Beyler et al	1-10
Y	US,A,4,269,831 published May 26, 1981 by Ferrari et al.	1-13
P,Y	US,A,4,439,432 published Mar. 27, 1984 by pest	1-13
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁴ Special categories of cited documents: ¹⁵</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ¹	Date of Mailing of this International Search Report ²	
9/12/85	26 FEB 1985	
International Searching Authority ³	Signature of Authorized Officer ¹⁹	
ISA/US	 Elbert L. Roberts	